title: Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.
abstract: Reduced intensity conditioning (RIC) regimens are widely used in allogeneic stem cell transplantation (SCT). In this study, we retrospectively investigated the clinical outcomes of RIC with fludarabine (Flu; 180 mg/m(2)), intravenous busulfan (BU; 6.4 mg/kg) or oral BU (8 mg/kg), and low-dose total body irradiation (TBI; 4 Gy) (Flu-BU2-TBI) in 66 patients (median age: 54.5 years) with various hematological malignancies. Thirty-eight patients (58%) were high-risk patients (median age: 56 years). The overall survival rate at 2 years of the high-risk patients was 64.5%, which was comparable to the survival rate of 70.9% in standard-risk patients (P = 0.68). The relapse rates at 2 years in the standard-risk and high-risk patients were 16 and 28%, respectively, and day 100 treatment-related mortality rates were 0 and 6%, respectively. The Flu-BU2-TBI regimen for high-risk patients showed therapeutic effects equivalent to those for standard-risk patients and favorable outcomes compared with those of other previous RIC regimens.
authors.affiliation: Hokkaido University Hospital, Sapporo, Hokkaido, Japan. mutsumit@qd5.so-net.ne.jp
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Takahata
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hashino
authors.forename: Kohei
authors.initials: K
authors.lastname: Okada
authors.forename: Masahiro
authors.initials: M
authors.lastname: Onozawa
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kahata
authors.forename: Junichi
authors.initials: J
authors.lastname: Sugita
authors.forename: Akio
authors.initials: A
authors.lastname: Shigematsu
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kondo
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Endo
authors.forename: Mitsufumi
authors.initials: M
authors.lastname: Nishio
authors.forename: Yoichi M
authors.initials: YM
authors.lastname: Ito
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Takao
authors.initials: T
authors.lastname: Koike
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Imamura
mesh_terms: D000328:Adult; D000368:Aged; D000375:Aging; D002066:Busulfan / Q000008:administration & dosage / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014916:Whole-Body Irradiation / Q000379:methods*
chemical_list: D019653:Myeloablative Agonists; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine